New Dual-Antibody drug could shrink stomach tumors before surgery
NCT ID NCT07595523
First seen May 22, 2026 · Last updated May 22, 2026
Summary
This study tests a new immunotherapy drug called iparomlimab tolvorlimab (QL1706) given before surgery to people with a specific type of advanced stomach cancer (MSI-H/dMMR). The goal is to see if the drug can shrink or eliminate the tumor, making surgery more effective. About 30 participants will receive the treatment, and researchers will monitor how well it works and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.